Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
Enovis (NYSE: ENOV) will showcase its expanding foot and ankle solutions portfolio at the ACFAS Annual Scientific Conference in Phoenix from March 27-30, 2025. The company will highlight several innovative products, including the new Tarsoplasty Percutaneous Lapidus Correction System for bunionectomy procedures.
The exhibition will feature advanced solutions such as OssiGraft Prime viable bone matrix allografts, Aircast AirSelect Elite pneumatic walking boot, Velocity+ proximal extension cuff, and Regeneration OL1000 bone growth stimulator. New research comparing the Arsenal Foot Plating System's screw angulation will also be presented.
The company will host two special events: 'Phoenix Rising: Foot & Ankle Edition' on March 28 and a Flatfoot/MIS Techniques Workshop on March 26.
Enovis (NYSE: ENOV) presenterà il suo portafoglio in espansione di soluzioni per piedi e caviglie alla Conferenza Scientifica Annuale ACFAS a Phoenix dal 27 al 30 marzo 2025. L'azienda metterà in evidenza diversi prodotti innovativi, incluso il nuovo Sistema di Correzione Lapidus Percutanea Tarsoplastica per procedure di bunionectomia.
L'esposizione presenterà soluzioni avanzate come OssiGraft Prime allograft di matrice ossea vitale, Aircast AirSelect Elite stivale pneumatico, Velocity+ manicotto di estensione prossimale e Regeneration OL1000 stimolatore di crescita ossea. Saranno presentati anche nuovi studi che confrontano l'angolazione delle viti del Sistema di Placcaggio Arsenal per il piede.
L'azienda ospiterà due eventi speciali: 'Phoenix Rising: Edizione Piede & Caviglia' il 28 marzo e un Workshop sulle Tecniche Flatfoot/MIS il 26 marzo.
Enovis (NYSE: ENOV) presentará su creciente portafolio de soluciones para pies y tobillos en la Conferencia Científica Anual ACFAS en Phoenix del 27 al 30 de marzo de 2025. La empresa destacará varios productos innovadores, incluido el nuevo Sistema de Corrección Percutánea Lapidus Tarsoplastia para procedimientos de bunionectomía.
La exposición contará con soluciones avanzadas como OssiGraft Prime aloinjertos de matriz ósea viable, Aircast AirSelect Elite bota de caminar neumática, Velocity+ manguito de extensión proximal y Regeneration OL1000 estimulador de crecimiento óseo. También se presentará nueva investigación que compara la angulación de tornillos del Sistema de Placas Arsenal para el pie.
La empresa organizará dos eventos especiales: 'Phoenix Rising: Edición Pie & Tobillo' el 28 de marzo y un Taller sobre Técnicas Flatfoot/MIS el 26 de marzo.
Enovis (NYSE: ENOV)는 2025년 3월 27일부터 30일까지 피닉스에서 열리는 ACFAS 연례 과학 회의에서 발과 발목 솔루션 포트폴리오의 확장을 선보일 예정입니다. 이 회사는 새롭게 출시된 타르소플라스티 경피성 라피두스 교정 시스템을 포함한 여러 혁신적인 제품을 강조할 것입니다.
전시회에서는 OssiGraft Prime 생체 골 매트릭스 동종이식편, Aircast AirSelect Elite 공기 압축 워킹 부츠, Velocity+ 근위 확장 커프, Regeneration OL1000 뼈 성장 자극기와 같은 첨단 솔루션이 소개됩니다. 또한 Arsenal Foot Plating System의 나사 각도 비교에 관한 새로운 연구도 발표될 예정입니다.
회사는 3월 28일 '피닉스 라이징: 발 & 발목 에디션'과 3월 26일 평발/MIS 기술 워크숍이라는 두 개의 특별 이벤트를 개최할 것입니다.
Enovis (NYSE: ENOV) présentera son portefeuille en expansion de solutions pour les pieds et les chevilles lors de la Conférence Scientifique Annuelle ACFAS à Phoenix du 27 au 30 mars 2025. L'entreprise mettra en avant plusieurs produits innovants, y compris le nouveau Système de Correction Lapidus Percutanée Tarsoplastie pour les procédures de bunionectomie.
L'exposition présentera des solutions avancées telles que OssiGraft Prime allogreffes de matrice osseuse viable, Aircast AirSelect Elite botte de marche pneumatique, Velocity+ manchon d'extension proximale et Regeneration OL1000 stimulateur de croissance osseuse. De nouvelles recherches comparant l'angulation des vis du Système de Plaques Arsenal pour le pied seront également présentées.
L'entreprise organisera deux événements spéciaux : 'Phoenix Rising : Édition Pied & Cheville' le 28 mars et un Atelier sur les Techniques Flatfoot/MIS le 26 mars.
Enovis (NYSE: ENOV) wird sein wachsendes Portfolio an Lösungen für Fuß- und Sprunggelenke auf der ACFAS Jahrestagung in Phoenix vom 27. bis 30. März 2025 präsentieren. Das Unternehmen wird mehrere innovative Produkte vorstellen, darunter das neue Tarsoplastik Perkutane Lapidus Korrektursystem für Bunionektomie-Verfahren.
Die Ausstellung wird fortschrittliche Lösungen wie OssiGraft Prime lebensfähige Knochenmatrix-Allografts, Aircast AirSelect Elite pneumatische Gehboot, Velocity+ proximale Erweiterungsmanschette und Regeneration OL1000 Knochensstimulator zeigen. Neue Forschungen zum Vergleich der Schraubenwinkel des Arsenal Fußplatten-Systems werden ebenfalls präsentiert.
Das Unternehmen wird zwei besondere Veranstaltungen ausrichten: 'Phoenix Rising: Fuß & Sprunggelenk Edition' am 28. März und einen Workshop zu Flachfuß/MIS-Techniken am 26. März.
- Launch of innovative Tarsoplasty system for minimally invasive bunion surgery
- Expansion of product portfolio with five advanced foot and ankle solutions
- New research data on Arsenal Foot Plating System's effectiveness
- None.
Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events.
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year’s American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.
Coupled with evidence-based technologies, Enovis Foot & Ankle will spotlight its commitment to surgeon education and hands-on training, reinforcing its mission to Redefine Every Step. "We’re transforming what partnership means in foot and ankle surgery," said Gary Justak, President and General Manager of Enovis Foot & Ankle. "Beyond innovative implants and advanced technologies, we provide the training, tools, and collaboration surgeons need to enhance surgical outcomes and restore motion for patients—every step of the way."
The new Tarsoplasty Percutaneous Lapidus Correction System—an innovative approach to Lapidus bunionectomy—will be among the solutions featured. “Tarsoplasty provides foot and ankle surgeons a percutaneous Lapidus option through a controlled, reproducible system,” said Bradley P. Abicht, DPM, FACFAS. “By reducing the surgical footprint, this technique enhances a patient’s perioperative experience."
The array of advanced solutions shown will include:
- Tarsoplasty™, an innovative, percutaneous approach to Lapidus bunionectomy.
- OssiGraft Prime™, viable bone matrix allografts meeting strict organ donation guidelines.
- Aircast® AirSelect™ Elite, Enovis’ most advanced pneumatic walking boot.
- Velocity+®, proximal extension cuff that provides added stability.
- Regeneration OL1000™, non-invasive, fracture nonunion bone growth stimulator.
Enovis will also highlight new research that compares the Arsenal Foot™ Plating System’s 30° screw angulation to 0–15°, examining how angulation, insertion sequence, and plate design influence compression and contact area—key factors in achieving stable fixation. A white paper with more information will be available at the Enovis booth.
Beyond the conference, Enovis invites attendees to two engagements bringing together leading experts to explore innovations transforming foot and ankle surgery. Enovis will host Phoenix Rising: Foot & Ankle Edition on March 28 from 6-9 p.m.; register here. Additionally, Enovis is sponsoring the Flatfoot/MIS Techniques Workshop (Cadaveric) on March 26, 1-5 p.m.
Visit booth 1820 to engage with Enovis products firsthand; for live updates during the conference, follow @enovisfootankle on Instagram and Enovis Foot & Ankle on LinkedIn.
About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.
*Dr. Abicht is a paid consultant of Enovis.
Media Contact
Rachel Colloff
Director, Corporate Communications
Rachel.Colloff@enovis.com
Attachment
